Categories: LEDManagementMedtechProduct
CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.01.2026 | Series D | $287M | - |
Mentions in press and media 6
| Date | Title | Description |
| 23.03.2026 | Everest Medicines Accelerates Global Ambitions with Key Acquisitions and Drug Launches | Everest Medicines is reshaping its market footprint. The biopharmaceutical giant secured rights to CARDAMYST™ (etripamil) nasal spray for Greater China. This innovative therapy targets paroxysmal supraventricular tachycardia (PSVT), offerin... |
| 23.03.2026 | Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize CARDAMYST™ (Etripamil) Nasal Spray in Greater China | SHANGHAI, March 23, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of ... |
| 26.01.2026 | Corxel Pharmaceuticals Raises $287M in Series D1 Funding | Corxel Pharmaceuticals, a Berkeley Heights, NJ-based clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic conditions, raised up to $287M in Series D1 funding.
Backers included new investors includi... |
| 26.01.2026 | Biopharma firm Corxel secures $287m to advance lead product pipeline | Corxel Pharmaceuticals, a clinical-stage biopharmaceutical company with operations in China and the US, has completed a Series D1 funding round at $287 million to support the advancement of its lead product candidate.
The Series D1 round at... |
| 22.01.2026 | Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug | In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral GLP-1 receptor agonist.
Shanghai-headquartered Corxel licens... |
| - | Corxel | - |
Reviews 0
